



## John D. Young\*

Nationality: British / American | Year of birth: 1964

A scientist by training, John D. Young has nearly 35 years of experience in the healthcare industry and will bring a wealth of experience in leadership, strategy, business development and commercialization of innovative medicines to the Novartis Board of Directors. He joined Pfizer in 1987 as a sales representative and held positions of increasing seniority across the company, including as a member of Pfizer's Executive Leadership Team from 2012. As Pfizer's Group President and Chief Business Officer from 2019 until 2022, John also played an integral role in the development and delivery of the Pfizer-BioNTech COVID-19 vaccine. He is independent from Novartis according to the independence criteria set forth by the Board of Directors.

### Professional experience

- Senior advisor to the CEO, Pfizer, US (January-June 2022)
- Group president and chief business officer, Pfizer, US (2019-2022)
- Group president, innovative health business, Pfizer, US (2018)
- Group president, essential health business, Pfizer, US (2014-2017)
- President and general manager, global primary care business unit, Pfizer, US (2012-2013)
- Regional president, primary care business unit for Europe and Canada, Pfizer, UK (2009-2012)
- Various managerial positions, Pfizer, UK and Australia (1987–2008)

### Mandates

- Board member, Johnson Controls International, Ireland
- Board member, Arvinas Inc, US
- Board member, Imbria Pharmaceuticals, US
- Board member, GSK Consumer Health Joint Venture, UK (2019-2022)
- Board member, Biotechnology Innovation Organization (BIO), US (2018-2021)
- US bio-pharmaceutical representative, UK Government Life Sciences Council, UK (2007-2021)
- Board member, National Committee for US China Relations, US (2014-2017)
- Board member, European Federation of Pharmaceutical Industries and Associations (EFPIA), Belgium (2012-2017)

### Education

- Master of Business Administration, University of Strathclyde, UK
- Bachelor of Science in biological sciences, University of Glasgow, UK

### Key skills

- Medicine/healthcare/R&D
- Leadership/management
- Finance/accounting
- Law/regulatory/risk management

\* This document has been updated. An earlier version showed a mandate as board member of Haleon PLC, UK. On January 31, 2023, Haleon PLC announced that John D. Young will be stepping down from the board of the company with effect from February 28, 2023.